| Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis |
Ongoing |
Purified Poloxamer 188 |
3 |
MST-188-01 |
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh), Maternity and Children's Hospital (Al Ahsa)_ King Fahad Medical City (Riyadh)_ King Abdulaziz University Hospital (Jeddah) |
| Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy and Safety of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Subjects With Congenital Fibrinogen Deficiency |
Ongoing |
Octafibrin |
3 |
Forma 02 |
King Khalid University Hospital (Riyadh) |
| A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer |
Ongoing |
Pertuzumab / Trastuzumab / Taxane |
3b |
MO28047 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah) |
| An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I) |
Ongoing |
ABT-450/r/ABT-267 ABT-333Ribavirin (RBV) |
3b |
M14-423 |
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| Risk assesment and mangement of Vte in women at risk of thromboEmbolism during pregnancy and puerperium |
Ongoing |
N/A |
4 |
OBS14159 |
King Abdulaziz University Hospital (Jeddah) |
| The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias |
Ongoing |
Deferiprone Deferoxamine |
3b |
LA38-0411 |
Aseer Central Hospital, King Abdulaziz University Hospital (Jeddah), King Khalid University Hospital (Riyadh) |
| A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) |
Ongoing |
(Sitagliptin / Metformin) |
3 |
MK0431-170 |
King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Hospital NG (Al Ahsa) |
| A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [SafeHer Study] |
Ongoing |
trastuzumab |
3 |
MO28048 |
King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh) |
| A Phase III Multicenter, Double-Blind, Randomized, Placebo- Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Release Metformin) in Pediatric Subjects with Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy |
Ongoing |
SITAGLIPTIN/ METFORMIN XR |
3 |
MK0431A XR-289 |
King Khalid University Hospital (Riyadh) |
| A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control |
Ongoing |
Sitagliptin |
3 |
MK0431-083 |
King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Hospital NG (Al Ahsa), Al-Noor Specialist Hospital (Makkah) |
